High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS
暂无分享,去创建一个
D. Arnold | G. Kraft | J. Bowen | M. Wener | O. Stuve | U. Popat | S. Devine | M. Racke | A. Wundes | P. Muraro | R. Nash | H. Openshaw | G. Hutton | P. Sayre | G. Georges | L. Griffith | Kaitlyn C Steinmiller | Linda M. Griffith
[1] D. Arnold,et al. Brain atrophy after bone marrow transplantation for treatment of multiple sclerosis , 2017, Multiple sclerosis.
[2] M. Sormani,et al. NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs , 2017, Multiple sclerosis.
[3] D. Arnold,et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial , 2016, The Lancet.
[4] K. Myhr,et al. Disease-modifying treatments for multiple sclerosis – a review of approved medications , 2015, European journal of neurology.
[5] M. Freedman,et al. Aggressive multiple sclerosis: proposed definition and treatment algorithm , 2015, Nature Reviews Neurology.
[6] M. Filippi,et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis , 2015, Neurology.
[7] H. Weiner,et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.
[8] D. Arnold,et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report. , 2015, JAMA neurology.
[9] M. Racke,et al. Is no evidence of disease activity a realistic goal for patients with multiple sclerosis? , 2015, JAMA neurology.
[10] Daniel C. Lee,et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. , 2015, JAMA.
[11] Carsten Lukas,et al. Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model , 2015, Therapeutic advances in neurological disorders.
[12] C. Desmarais,et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. , 2014, The Journal of clinical investigation.
[13] J. Johansson,et al. Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[14] M. Sormani,et al. MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials , 2013, The Lancet Neurology.
[15] Christian Confavreux,et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial , 2012, The Lancet.
[16] M. Sormani,et al. Autologous haematopoietic stem cell transplantation with an intermediate intensity conditioning regimen in multiple sclerosis: the Italian multi-centre experience , 2012, Multiple sclerosis.
[17] H. Atkins,et al. A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper , 2012, Multiple sclerosis.
[18] G. Kraft,et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results , 2011, Bone Marrow Transplantation.
[19] L. Roccatagliata,et al. Surrogate endpoints for EDSS worsening in multiple sclerosis , 2010, Neurology.
[20] M. Labopin,et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years’ experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases , 2010, Haematologica.
[21] Hans Lassmann,et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains , 2009, Brain : a journal of neurology.
[22] C. Polman,et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study , 2009, The Lancet Neurology.
[23] A. Testori,et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study , 2009, The Lancet Neurology.
[24] A. Thompson,et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. , 2008, Brain : a journal of neurology.
[25] G. Ingram,et al. Change in disability in patients with multiple sclerosis: a 20-year prospective population-based analysis , 2008, Journal of Neurology, Neurosurgery, and Psychiatry.
[26] M. Filippi,et al. The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study , 2007, Multiple sclerosis.
[27] D. Arnold,et al. Brain atrophy after immunoablation and stem cell transplantation in multiple sclerosis , 2006, Neurology.
[28] Gavin Giovannoni,et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. , 2005, Archives of neurology.
[29] D. Douek,et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients , 2005, The Journal of experimental medicine.
[30] Y. Blanco,et al. Autologous haematopoietic-stem-cell transplantation for multiple sclerosis , 2005, The Lancet Neurology.
[31] G. Kraft,et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. , 2003, Blood.
[32] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[33] J. Yagüe,et al. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS , 2001, Neurology.
[34] Stephen M. Rao,et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. , 1999, Brain : a journal of neurology.
[35] A. Anagnostopoulos,et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study , 1997, Bone Marrow Transplantation.
[36] J V Hajnal,et al. Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. , 1996, AJNR. American journal of neuroradiology.
[37] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[38] D. Altmann,et al. Disability and T 2 MRI lesions: a 20 -year follow-up of patients with relapse onset of multiple sclerosis , 2008 .